Direct factory supply manufactured in accordance with strict pharmacopeial monographs, providing high chromatographic purity (≥99.0%), low bacterial endotoxin thresholds, and scalable batch capacities.
An in-depth chemical and pharmacological analysis of Glucagon-Like Peptide-2 receptor agonists, secondary structure stabilization, and chemical synthesis strategies for clinical and commercial drug programs.
Native human Glucagon-Like Peptide-2 is a 33-amino acid proglucagon-derived peptide co-secreted with GLP-1 by enteroendocrine L-cells in the ileum and colon upon nutrient ingestion. However, endogenous GLP-2 exhibits an in vivo half-life of merely 7 minutes due to instantaneous enzymatic cleavage by Dipeptidyl Peptidase-4 (DPP-IV) at the Ala2 position. Therapeutic GLP-2 analogues substitute native alanine at position 2 with [Gly2], [D-Ala2], or extend the sequence via fatty acid acylation or C-terminal poly-lysine tails, amplifying receptor residence time and extending systemic pharmacokinetics beyond 50 hours.
While Teduglutide ([Gly2]GLP-2) stands as the benchmark FDA/EMA-approved therapeutic for adult and pediatric Short Bowel Syndrome-associated Intestinal Failure (SBS-IF), next-generation candidates such as Glepaglutide (a 39-amino acid peptide with a C-terminal hexalysine tail) and Apraglutide (a site-specifically substituted, chemically stabilized analogue optimized for weekly dosing) represent major breakthroughs. In commercial chemical synthesis, each analogue presents unique steric encumbrances, requiring tailored orthogonal protecting group strategies (Fmoc/tBu vs. Boc/Bzl) and continuous-flow monitoring to prevent aggregation during fragment condensation.
Binding of GLP-2 analogues to the GLP-2 receptor (GLP2R)—a G protein-coupled receptor localized on subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells—activates cyclic adenosine monophosphate (cAMP) and intracellular calcium cascades. This stimulates the local release of paracrine mediators including Insulin-like Growth Factor-1 (IGF-1), keratinocyte growth factor (KGF), and endothelial nitric oxide synthase (eNOS). The resulting cellular cascade stimulates crypt cell proliferation, inhibits enterocyte apoptosis, expands villus height, elevates nutrient transporter expression (SGLT-1, GLUT2), and enforces intestinal epithelial barrier integrity.
| Peptide Molecule | CAS Registry Number | Amino Acid Sequence Length | Structural Modification Route | Primary Clinical & R&D Target | Supply Format Availability |
|---|---|---|---|---|---|
| Teduglutide | 197922-42-2 | 33 Amino Acids | [Gly2] substitution preventing DPP-IV degradation | Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) | Multi-Kg Commercial API |
| Glepaglutide | 2171120-74-4 | 39 Amino Acids | C-terminal Hexalysine extension, altered pI for solubility | Subcutaneous liquid formulation for weekly SBS regimens | Custom Pilot & Commercial |
| Apraglutide | 1628956-65-7 | 33 Amino Acids | Unnatural amino acid substitutions at positions 11, 16, 20, 24 | Gastrointestinal Graft-versus-Host Disease (GI-GvHD), SBS-IF | High-Purity R&D / CDMO Batch |
| Dual GLP-1 / GLP-2 Co-Agonists | Proprietary Pipeline | 37-44 Amino Acids | Fatty diacid side chain acylation, dual receptor affinity | Metabolic dysfunction, NASH/MASH with intestinal hyperpermeability | Pre-clinical Custom Synthesis |
Combining world-scale solid-phase peptide synthesis (SPPS), optimized green raw material supply chains, advanced automated purification, and multi-ton synthesis capabilities in Hangzhou, China.
Our centralized manufacturing facility in Qiantang District, Hangzhou, hosts fully automated 1000L to 3000L solid-phase reaction vessels, enabling multi-ton aggregate output per annum. This scale insulates overseas sponsors from supply interruptions caused by raw material constraints.
Operating under strict cGMP environments, our R&D and production sites feature class 100,000 synthesis workshops, class 10,000 purification zones, and clean-in-place class 100 sterile isolation isolators with complete 21 CFR Part 11 electronic data traceability.
By establishing localized procurement pipelines for Fmoc-protected amino acids, specialized coupling reagents (HBTU, HATU, DIC/OxymaPure), and proprietary polystyrene and Wang resins, Thinheal minimizes cost-per-gram expenses by 35% to 50% relative to Western counterparts.
GLP-2 analogues are prone to beta-aspartyl rearrangement, D-enantiomer racemization, and Trp/Met oxidation. Our analytical core deploys high-resolution Orbitrap LC-MS, 2D-UPLC, and orthogonal preparative DAC columns, guaranteeing single unknown impurities <0.10%.
The global incretin boom is sparking a renaissance in peptide therapeutics. Explore how GLP-2 analogues are transitioning from orphan drug statuses into high-volume clinical indications.
Cancer cytotoxic therapies frequently destroy rapid-dividing intestinal crypt enterocytes, triggering severe oral and alimentary canal mucositis, intractable diarrhea, and severe malnutrition. Preclinical and translational oncology trials confirm that prophylactic or early-stage administration of long-acting GLP-2 analogues accelerates mucosal regeneration, preserves intestinal tight junctions (Claudin-1, Occludin, ZO-1), prevents bacterial translocation, and mitigates chemotherapy-induced gastrointestinal toxicity.
Acute GI-GvHD following allogeneic hematopoietic stem cell transplantation remains a fatal complication characterized by immunologic destruction of intestinal stem cell niches and mucosal shedding. Fast-track orphan designations granted to candidates like Apraglutide underscore the urgent clinical need for mucosal reparative peptides that restore gut homeostasis independently of systemic immunosuppressive corticosteroids, driving intense contract research and API manufacturing demand.
The convergence of metabolic disease and intestinal barrier leakage (leaky gut syndrome) has illuminated the strategic potential of unimolecular dual incretin receptor agonists. While GLP-1 governs glycemic control, gastric emptying deceleration, and hypothalamic satiety signaling, GLP-2 reinforces gut mucosal thickness, diminishes endotoxemia (circulating LPS), and ameliorates chronic low-grade systemic inflammation linked with NASH/MASH and severe hepatic steatosis.
Before issuing commercial purchase orders for custom peptides or bulk active pharmaceutical ingredients, global sourcing managers and quality assurance teams require rigorous validation across six analytical domains.
Peptide synthesis via trifluoroacetic acid (TFA) cleavage protocols naturally leaves substantial residual TFA counter-ions (often 10% to 25% by weight). For human injectables and sensitive biological formulations, TFA generates cellular cytotoxicity and alters pH stability. Thinheal utilizes continuous ion-exchange chromatography paired with dynamic diafiltration to convert TFA to acetate or chloride salts, ensuring residual TFA is stringently constrained to ≤0.1% or ≤0.05% w/w while achieving exact Net Peptide Content (NPC) calculations.
During the elongation of long-chain 33-mer to 39-mer sequences, racemization of sensitive residues (such as Cysteine, Histidine, and Serine) into D-enantiomeric isoforms creates truncated or diastereomeric impurities that are indistinguishable from the target peptide by standard mass spectrometry alone. Thinheal deploys specialized chiral gas chromatography-mass spectrometry (GC-MS) following complete deuterium-acid hydrolysis to verify optical purity ≥99.8% across every critical residue.
Traditional SPPS depends heavily on DMF, NMP, and DCM, which face stringent restrictions under ICH Q3C(R8) guidelines due to occupational toxicity and reproductive risks. At Thinheal, our R&D laboratories have pioneered green peptide synthesis protocols utilizing CPME (Cyclopentyl methyl ether) and 2-MeTHF as benign reaction media, backed by dual Headspace Gas Chromatography (HS-GC) detection to assure residual solvent residues remain far below international safety thresholds.
Gastrointestinal and systemic therapeutics demand exceptional bioburden control to eliminate pyrogenic reactions in patients. Thinheal’s specialized manufacturing units utilize depyrogenated glassware, high-purity Water-for-Injection (WFI) systems generating TOC <10 ppb, and validated 0.22-micron PES membrane filtering steps inside Class 100 cleanroom environments before controlled lyophilization cycles.
Whether procuring pilot-scale milligrams for target validation or multi-kilogram active pharmaceutical ingredients for regulatory registration batches, explore our structured volume-indexed pricing models.
Designed for academic institutes, biotech screening programs, and in vitro assay profiling. Products are supplied with standard TFA or basic acetate salts, comprehensive HPLC purity (≥95% or ≥98%), and high-resolution ESI-MS validation charts. Turnaround windows range between 2 to 3 weeks for milligram-to-gram sequences.
Tailored for non-GLP/GLP animal toxicology, formulation feasibility screening, and pharmacokinetic characterization. Features strict TFA removal, validated acetate counter-ion stoichiometry, low bioburden thresholds, and comprehensive stability profiling under ICH conditions.
Full-scale commercial production for human drug formulation and global marketing authorizations. Includes validation of three consecutive commercial batches, process analytical technology (PAT) logs, Drug Master File (DMF / ASMF) submission support, and customer audit access.
In-depth responses compiled by Thinheal's senior peptide process chemists and quality assurance directors to address the key procurement, synthesis, and compliance concerns of global pharmaceutical clients.
Teduglutide is synthesized primarily via automated Solid-Phase Peptide Synthesis (SPPS) using an orthogonal Fmoc/tBu protecting group strategy on high-capacity Wang resin or 2-chlorotrityl chloride (CTC) resin. For large commercial batches, hybrid synthesis (coupling protected peptide fragments in solution phase) is also evaluated to optimize atom economy and total cycle time. Crude cleavage is executed using a customized trifluoroacetic acid (TFA) cocktail containing triisopropylsilane (TIS), EDT, and water to minimize carbocation alkylation on sensitive tryptophan (Trp) and methionine (Met) residues.
GLP-2 contains multiple aspartic acid residues that are susceptible to aspartimide rearrangement under repeated piperidine deprotection cycles during SPPS, leading to undesired β-aspartyl peptides. Thinheal deploys specialized backbone amide protection strategies, such as (Dmb) or (Hmb) protected dipeptide building blocks (e.g., Fmoc-Asp(OtBu)-(Dmb)Gly-OH), or employs weak organic bases like piperazine with acidic additives (such as formic acid or HOBt) to inhibit aspartimide ring closure during elongation, suppressing β-isomer impurities below 0.15%.
HPLC purity measures the relative percentage of the target peptide peak against other UV-absorbing impurities in the chromatographic profile. In contrast, Net Peptide Content measures the true fraction of actual peptide material present in the lyophilized powder, accounting for non-peptide constituents such as residual water (Karl Fischer moisture), residual organic solvents, and counter-ion salts (acetate, TFA, sodium). While a batch may exhibit ≥99.0% HPLC purity, its Net Peptide Content typically ranges from 75% to 88%. Calculating exact peptide content is indispensable for accurate therapeutic dosage formulation.
For research and pilot quantities, each shipment includes a batch-specific Certificate of Analysis (CoA), reverse-phase analytical HPLC traces, and Electrospray Ionization Mass Spectrometry (ESI-MS) reports. For commercial and clinical cGMP campaigns, Thinheal delivers full Chemistry, Manufacturing, and Controls (CMC) technical files compliant with CTD Module 3 formatting. This encompasses process validation protocols, analytical method validations (ICH Q2(R1)), stability study reports under accelerated and real-time conditions (ICH Q1A(R2)), residual solvent screening, and Drug Master File (DMF) open-part filings.
Lyophilized GLP-2 analogues are packaged in depyrogenated type I borosilicate glass vials sealed with fluoropolymer-coated chlorobutyl rubber stoppers under dry nitrogen or argon headspaces. For intercontinental dispatch to Europe, North America, and East Asia, materials are placed in validated VIP (Vacuum Insulated Panel) thermal shipping systems containing calibrated -20°C phase-change PCM packs or dry ice blocks, equipped with real-time Sensitech or TempTale electronic temperature and GPS loggers.
Yes. Our Hangzhou R&D center is specialized in executing advanced post-synthetic modifications, including the site-selective acylation of lysine residues with lipid side chains (e.g., mono-tert-butyl octadecanedioate or diacid spacers via γ-Glu-OEG-OEG linkers). We possess established automated process platforms for multi-branched, cyclic disulfide, and PEGylated peptide analogues, allowing pharmaceutical partners to scale novel gastrointestinal co-agonists from 500 mg lead optimization to 20 kg validation batches.
Explore our extensive commercial inventory covering advanced metabolic analogues, neuroprotective peptides, GI regulators, and hypothalamic releasing hormone mimics manufactured under stringent quality protocols.
Thin